Asset Acquisitions (Details) - USD ($) $ in Thousands			3 Months Ended		9 Months Ended	12 Months Ended
	Jan. 04, 2024	Feb. 27, 2023	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Dec. 31, 2023
Asset Acquisition
Issuance of stock				$ 48,875
Issuance of common stock as consideration for LGC license			$ 18,716
L G Chem Ltd
Asset Acquisition
Aggregate payment upon achievement of development and commercial milestones	$ 205,000
Purchase consideration	92,400
Cash consideration	40,000
Issuance of stock	20,000
Issuance of common stock as consideration for LGC license	18,700
License agreement consideration payment	$ 40,000
Effective date of the license agreement	18 months
License fee payable	$ 33,700				$ 36,600
L G Chem Ltd | Research and development
Asset Acquisition
Purchase consideration					$ 92,400
L G Chem Ltd | Selling, general and administrative
Asset Acquisition
Acquisition related costs	$ 800
Xinvento B.V.
Asset Acquisition
Aggregate payment upon achievement of development and commercial milestones		$ 206,000
Clinical development milestone payments		6,000
Regulatory approval and commercial milestones milestone payments		125,000
Sales milestone payments		75,000
Purchase consideration		5,667
Cash consideration		4,520
Holdback, payable on the one-year anniversary of the acquisition		500
Acquisition related costs		$ 647
Xinvento B.V. | Research and development
Asset Acquisition
Purchase consideration						$ 5,667